相关实验视频

Updated: Sep 20, 2025

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

在转移性ALK阳性NSCLC中使用alectinib治疗的Oligo-残留性疾病

Xi Yang^1,2,3,4, Xiao Chu^1,2,3,4, Ruiting Ye^1,2,3,4

¹Department of Radiation Oncology, Fudan University Shanghai Cancer Center, 270 Dong An Road, Shanghai, 200032, China.

Clinical & experimental metastasis

|May 29, 2025

概括

橄残留性疾病 (ORD) 常见于转移性ALK阳性NSCLC患者,这些患者接受过alectinib治疗. 许多ORD患者在残留部位经历了初始进展,这表明局部巩固疗法可能有利于这些患者.

科学领域:

在瘤学瘤学.
医学研究医学研究
临床试验临床试验

背景情况:

局部巩固疗法 (LCT) 可能在全身疗法后延迟转移性NSCLC与橄残留性疾病 (ORD) 的耐药性.
在接受阿莱克提尼布治疗的转移性ALK阳性NSCLC中,ORD的发病率和特征尚不清楚.

研究的目的:

确定接受alectinib的转移ALK阳性NSCLC患者ORD的发病率和临床特征.
分析LCT在该患者群体中的复发模式和潜在益处.

主要方法:

对128名转移ALK阳性NSCLC患者的序列扫描进行了回顾性审查,这些患者接受了alectinib治疗.
ORD定义为在对阿莱克提尼布的部分反应 (PR) 后,≤5个残留的转移性病变.
复发模式分为剩余地点复发 (RR),新地点复发 (NR) 或两者兼而有之 (RNR).

主要成果:

在62名PR患者中,18名 (29.0%) 患有ORD.
没有确定ORD的独立预测因子.
50.0%的ORD患者进展,主要在残留部位 (55.6%),66.7%的基线脑损伤,通常局限于残留脑部位 (50.0%).

结论:

在接受阿莱克提尼布治疗的ALK阳性NSCLC中,ORD并不罕见.
最初的进展通常发生在残留部位,包括中枢神经系统.
这些发现支持对ORD患者的LCT进行探索,以潜在地克服获得的耐药性.

关键词:

亚纳普拉斯性淋巴瘤激酶转位的转位.非小细胞肺癌是非小细胞肺癌.橄残留病是一种残留性疾病.有针对性的治疗.

更多相关视频

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...